Drug
Bemarituzumab
Bemarituzumab: highest development phase Phase 3, developed by Amgen, United Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Amgen, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Bemarituzumab NCT05052801 | Phase 3 | Gastric Cancer |
| Bemarituzumab NCT03694522 | Phase 2 | Gastric Cancer |
Latest
No recent events.
Follow Bemarituzumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.